Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EPCORE DLBCL-1
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- NCT04628494 ↗
- Active, not recruiting
- Genmab
- Standard
We haven't built an HCP commentary report on EPCORE DLBCL-1 (epcoritamab in relapsed/refractory diffuse large B-cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EPCORE DLBCL-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Epcoritamab; Investigator's Choice Chemotherapy
- Arms
- Epcoritamab (GEN3013; DuoBody®CD3xCD20) · Experimental
- Investigator's choice of chemotherapy · Active comparator
- Enrollment
- 483
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Genmab with AbbVie
- Start
- Jan 13, 2021
- Primary completion
- Oct 13, 2025
- Results posted
- No
- Registry record
- NCT04628494 · updated May 22, 2026